µ¿¹° ¸ðµ¨ ½ÃÀå : ½ÃÀå ºÐ¼® ¹× ¿¹Ãø(-2033³â) - À¯Çüº°, Á¦Ç°º°, ¼­ºñ½ºº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ÄÄÆ÷³ÍÆ®º°, ±â´Éº°, ÀνºÅç ŸÀÔº°
Animal Model Market Analysis and Forecast to 2033: Type, Product, Services, Technology, Application, End User, Component, Functionality, Installation Type
»óǰÄÚµå : 1634059
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 395 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,517,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 7,889,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,261,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µ¿¹° ¸ðµ¨ ½ÃÀåÀº CAGR 7.3%¸¦ ¹Ý¿µÇÏ¿© 2023³â 24¾ï ´Þ·¯¿¡¼­ 2033³â 50¾ï ´Þ·¯·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µ¿¹° ¸ðµ¨ ½ÃÀå¿¡´Â ÁÖ·Î ÀǾàǰ °³¹ß ¹× »ý¹° ÀÇÇÐ ¿¬±¸¿¡¼­ »ý¹°ÇÐÀû ¹× º´¸®ÇÐÀû °úÁ¤À» ÀÌÇØÇϱâ À§ÇÑ ½ÃÇè ¹× ¿¬±¸¿¡ Àΰ£ ÀÌ¿ÜÀÇ µ¿¹°À» °³¹ß ¹× »ç¿ëÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀå¿¡´Â À¯ÀüÀÚ Á¶ÀÛ ¸ðµ¨, Áúº´ ƯÀÌÀû ¸ðµ¨, ÀüÀÓ»ó½ÃÇèÀ» ÃËÁøÇÏ´Â ¼­ºñ½º µîÀÌ Æ÷ÇԵǸç, Àΰ£ÀÇ Áúº´°ú Ä¡·á È¿°ú¿¡ ´ëÇÑ Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÏ¿© ÀÇ·á ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

µ¿¹° ¸ðµ¨ ½ÃÀåÀº ÁÖ·Î »ýÀÇÇÐ ¿¬±¸¿Í ÀǾàǰ °³¹ßÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¼³Ä¡·ù ¸ðµ¨, ƯÈ÷ ¸¶¿ì½º¿Í Áã´Â Àΰ£°úÀÇ À¯ÀüÀû À¯»ç¼º°ú ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ºñÀΰ£ ¿µÀå·ù´Â ±×´ÙÁö ³Î¸® º¸±ÞµÇÁö´Â ¾Ê¾ÒÁö¸¸, º¹ÀâÇÑ Áúº´ ¸ðµ¨¸µ°ú Áß°³¿¬±¸¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ¹Ý¿µÇÏ¿© µÎ ¹øÂ°·Î ³ôÀº ¼º°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â Àß ±¸ÃàµÈ ¿¬±¸ ÀÎÇÁ¶ó¿Í »ý¸í°úÇп¡ ´ëÇÑ ¸·´ëÇÑ ÀÚ±Ý Áö¿øÀ» ¹ÙÅÁÀ¸·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ±ÔÁ¦ ȯ°æ °³¼±¿¡ ÈûÀÔ¾î µÎ ¹øÂ°·Î ³ôÀº ¼º°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ Áß ¹Ì±¹°ú µ¶ÀÏÀº À¯Àü°øÇÐ ¹× ¸ÂÃãÀÇ·á ºÐ¾ß¿¡¼­ °ý¸ñÇÒ ¸¸ÇÑ ÁøÀüÀ» º¸À̰í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÅÈï ½ÃÀå, ƯÈ÷ Áß±¹°ú Àεµ´Â »ý¸í°øÇÐ ºÐ¾ßÀÇ ¼ºÀå°ú ÇコÄɾî Çõ½Å¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªµ¿ÀûÀΠȯ°æÀº µ¿¹° ¸ðµ¨ ½ÃÀå Àü¹Ý¿¡ °ÉÃÄ ÀÌÇØ°ü°èÀڵ鿡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

2023³â¿¡´Â »ý¹° ÀÇÇÐ ¿¬±¸¿¡ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ¸é¼­ ¼³Ä¡·ù ¸ðµ¨ÀÌ 50% ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ´Â µî ½ÃÀå ¼¼ºÐÈ­°¡ ¶Ñ·ÇÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. °³¿Í ¿µÀå·ù¸¦ Æ÷ÇÔÇÑ ºñ¼³Ä¡·ù ¸ðµ¨Àº º¹ÀâÇÑ Áúº´ ¿¬±¸¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ¹Ý¿µÇÏ¿© 30%¸¦ Â÷ÁöÇÕ´Ï´Ù. Àΰ£°úÀÇ À¯ÀüÀû À¯»ç¼º ¶§¹®¿¡ Àα⸦ ²ø°í ÀÖ´Â ¾ó·è¸»Àº 15%¸¦ Â÷ÁöÇß½À´Ï´Ù. ³ª¸ÓÁö 5%´Â ±âŸ µ¿¹° ¸ðµ¨ÀÔ´Ï´Ù. ¼ö·® µ¥ÀÌÅÍ´Â Á¦¾à ¹× Çмú ¿¬±¸ ºÐ¾ß Àü¹Ý¿¡ °ÉÃÄ ÀÌ·¯ÇÑ µ¿¹° ¸ðµ¨ÀÌ »ó´çÈ÷ ¸¹ÀÌ È°¿ëµÇ°í ÀÖÀ½À» º¸¿©ÁÖ¸ç, ÀüÀÓ»ó½ÃÇè¿¡ ÇʼöÀûÀÓÀ» °­Á¶ÇÕ´Ï´Ù.

°æÀï ±¸µµ´Â ÷´Ü À¯ÀüÀÚ ±â¼úÀ» Ȱ¿ëÇÏ¿© ¸ðµ¨ÀÇ È¿´ÉÀ» ³ôÀ̰í ÀÖ´Â Charles River Laboratories¿Í Envigo°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ FDAÀÇ µ¿¹°½ÇÇè °¡À̵å¶óÀΰú °°Àº ±ÔÁ¦ÀÇ ¿µÇâÀº ½ÃÀå ¿î¿µ¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ±ÔÁ¤ Áؼö¿Í À±¸®Àû °í·ÁÀÇ Çʿ伺À» Ã˱¸Çϰí ÀÖÀ¸¸ç, 2033³â±îÁö 8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)ÀÌ ¿¹»óµÇ¾î ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CRISPR ±â¼úÀÇ Çõ½Å°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡´Â À¯ÀüÀÚ Á¶ÀÛ ¸ðµ¨ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯ÀüÀÚ Á¶ÀÛ ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå È®´ë¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. À̴ źźÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í »ý¹° ÀÇÇÐ ¿¬±¸¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿¡ ±âÀÎÇÕ´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ¼±ÁøÀûÀÎ ÀÇ·á ºÎ¹®°ú ¼ö¸¹Àº ¿¬±¸ ±â°üÀ¸·Î ÀÎÇØ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ÀçÁ¤ Áö¿ø°ú ¿¬±¸ Áö¿øÀº ÀÌ Áö¿ª ½ÃÀå ÁöÀ§¸¦ ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù.

À¯·´Àº µ¿¹° ¸ðµ¨ ½ÃÀå¿¡¼­ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº Àß È®¸³µÈ Á¦¾à »ê¾÷°ú ¿¬±¸°³¹ß¿¡ ´ëÇÑ °­ÇÑ ÁýÁßÀ¸·Î ÀÌÀÍÀ» ¾ò°í ÀÖ½À´Ï´Ù. µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹°ú °°Àº ±¹°¡µéÀº ±â¼ú Çõ½Å°ú ±â¼ú ¹ßÀüÀ» ÅëÇØ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº µ¿¹° ¸ðµ¨ ½ÃÀå¿¡¼­ ºü¸¥ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ´Â ¿¬±¸ Ȱµ¿ Áõ°¡¿Í »ý¸í°øÇп¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. Áß±¹°ú Àεµ´Â Á¦¾à »ê¾÷ÀÇ È®Àå°ú Çõ½ÅÀûÀÎ ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÌ ÀÇ·á ÀÎÇÁ¶ó °³¼±¿¡ ÁýÁßÇϰí ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù.

¶óƾ¾Æ¸Þ¸®Ä«´Â µ¿¹°¸ðµ¨ÀÇ À¯¸ÁÇÑ ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ºê¶óÁú°ú ¸ß½ÃÄÚ°¡ ÀÌ Áö¿ªÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡´Â Á¦¾à ¹× »ý¸í°øÇÐ ºÎ¹®ÀÌ ¼ºÀåÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ °úÇÐ ¿¬±¸ Áö¿ø Á¤Ã¥Àº ÀÌ Áö¿ªÀÇ ÀáÀç·ÂÀ» ´õ¿í ³ô¿©ÁÖ°í ÀÖ½À´Ï´Ù.

Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µ¿¹° ¸ðµ¨ ½ÃÀå Á¡À¯À²Àº ÀÛ½À´Ï´Ù. ±×·¯³ª ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ³²¾ÆÇÁ¸®Ä«°øÈ­±¹, ¾Æ¶ø¿¡¹Ì¸®Æ®¿Í °°Àº ±¹°¡µéÀº ¿¬±¸ ¿ª·® °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÇ Á¡ÁøÀûÀÎ ½ÃÀå °³Ã´¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå µ¿¹° ¸ðµ¨ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ ÇÁ¸®¹Ì¾ö ÀλçÀÌÆ®

Á¦4Àå µ¿¹° ¸ðµ¨ ½ÃÀå Àü¸Á

Á¦5Àå µ¿¹° ¸ðµ¨ ½ÃÀå Àü·«

Á¦6Àå µ¿¹° ¸ðµ¨ ½ÃÀå ±Ô¸ð

Á¦7Àå µ¿¹° ¸ðµ¨ ½ÃÀå : À¯Çüº°

Á¦8Àå µ¿¹° ¸ðµ¨ ½ÃÀå : Á¦Ç°º°

Á¦9Àå µ¿¹° ¸ðµ¨ ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå µ¿¹° ¸ðµ¨ ½ÃÀå : ±â¼úº°

Á¦11Àå µ¿¹° ¸ðµ¨ ½ÃÀå : ¿ëµµº°

Á¦12Àå µ¿¹° ¸ðµ¨ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦13Àå µ¿¹° ¸ðµ¨ ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

Á¦14Àå µ¿¹° ¸ðµ¨ ½ÃÀå : ±â´Éº°

Á¦15Àå µ¿¹° ¸ðµ¨ ½ÃÀå : ÀνºÅç ŸÀÔº°

Á¦16Àå µ¿¹° ¸ðµ¨ ½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The animal model market is anticipated to expand from $2.4 billion in 2023 to $5.0 billion by 2033, reflecting a compound annual growth rate (CAGR) of 7.3%.

The animal model market encompasses the development and use of non-human animals for testing and research to understand biological and pathological processes, primarily in drug development and biomedical research. This market includes genetically engineered models, disease-specific models, and services that facilitate preclinical trials, contributing to advancements in healthcare by providing critical insights into human diseases and therapeutic efficacy.

The animal model market is witnessing robust growth, primarily driven by advancements in biomedical research and drug development. Rodent models, particularly mice and rats, dominate the market due to their genetic similarities to humans and cost-effectiveness. Non-human primates, though less prevalent, are the second-highest performing sub-segment, reflecting their critical role in complex disease modeling and translational research. The North American region leads the market, supported by well-established research infrastructure and substantial funding for life sciences. Europe follows as the second-highest performing region, driven by increasing investments in research and development and a supportive regulatory environment. Within these regions, the United States and Germany are the standout countries, showcasing significant advancements in genetic engineering and personalized medicine. Emerging markets in Asia-Pacific, notably China and India, are gaining momentum, fueled by growing biotechnology sectors and increased focus on healthcare innovation. This dynamic landscape presents lucrative opportunities for stakeholders across the animal model market.

In 2023, the market demonstrated robust segmentation with the rodent models holding a commanding 50% market share, driven by their extensive use in biomedical research. Non-rodent models, including canines and primates, accounted for 30%, reflecting their critical role in complex disease studies. Zebrafish models, gaining traction due to their genetic similarity to humans, captured 15%. The remaining 5% was comprised of other emerging models. Volume data indicates a significant utilization of these models across pharmaceutical and academic research sectors, underscoring their indispensability in preclinical trials.

The competitive landscape is dominated by Charles River Laboratories and Envigo, who are leveraging advanced genetic technology to enhance model efficacy. Regulatory influences, such as the U.S. FDA's guidelines on animal testing, significantly impact market operations, driving the need for compliance and ethical considerations. Looking ahead, the market is poised for growth. Innovations in CRISPR technology and an increasing focus on personalized medicine are anticipated to propel demand for genetically engineered models, presenting lucrative opportunities for market expansion.

North America dominates the market. This is due to robust research infrastructure and significant investment in biomedical research. The United States, in particular, is a major contributor, driven by its advanced healthcare sector and numerous research institutions. Government funding and support for research further enhance the region's market position.

Europe holds a substantial share in the animal model market. The region benefits from a well-established pharmaceutical industry and a strong focus on research and development. Countries like Germany, France, and the United Kingdom are key players, contributing to market growth through innovation and technological advancements.

Asia Pacific is experiencing rapid growth in the animal model market. This is fueled by increasing research activities and rising investments in biotechnology. China and India are at the forefront, with expanding pharmaceutical industries and growing demand for innovative healthcare solutions. The region's focus on improving healthcare infrastructure also supports market expansion.

Latin America is emerging as a promising market for animal models. Brazil and Mexico lead the region, driven by rising investments in research and development. The growing pharmaceutical and biotechnology sectors in these countries contribute to market growth. Government initiatives to support scientific research further bolster the region's potential.

The Middle East and Africa hold a smaller share in the animal model market. However, increasing healthcare awareness and investments in research are driving growth. Countries like South Africa and the UAE are making strides in developing their research capabilities, contributing to the region's gradual market expansion.

Key Companies

Taconic Biosciences, Envigo, Charles River Laboratories, Janvier Labs, Gen Oway, The Jackson Laboratory, Harlan Laboratories, SAGE Labs, Transposagen Biopharmaceuticals, Crown Bioscience, Phoenix Bio, Ozgene, Cyagen Biosciences, Hera Bio Labs, Biocytogen, In Vivos, Psychogenics, Mispro Biotech Services, Axis Pharm, Creative Animodel

Sources

National Institutes of Health (NIH), European Commission - Research and Innovation, U.S. Food and Drug Administration (FDA), World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD) - Science, Technology and Innovation, National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), European Medicines Agency (EMA), The Jackson Laboratory, American Association for Laboratory Animal Science (AALAS), International Council for Laboratory Animal Science (ICLAS), Federation of American Societies for Experimental Biology (FASEB), Society for Laboratory Animal Science (GV-SOLAS), International Society for Transgenic Technologies (ISTT), World Congress on Alternatives and Animal Use in the Life Sciences, American College of Laboratory Animal Medicine (ACLAM), Laboratory Animal Science Association (LASA), International Conference on Animal Models and Experimental Medicine, Animal Models and Human Disease Conference, Society for In Vitro Biology (SIVB), Johns Hopkins University Center for Alternatives to Animal Testing (CAAT)

Research Scope

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Animal Model Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Animal Model Market Outlook

5: Animal Model Market Strategy

6: Animal Model Market Size

7: Animal Model Market, by Type

8: Animal Model Market, by Product

9: Animal Model Market, by Services

10: Animal Model Market, by Technology

11: Animal Model Market, by Application

12: Animal Model Market, by End User

13: Animal Model Market, by Component

14: Animal Model Market, by Functionality

15: Animal Model Market, by Installation Type

16: Animal Model Market, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â